Lilly to Supply an Additional 150,000 Doses of AbCellera-Discovered Antibody, Bebtelovimab, to the U.S. Government in Ongoing Effort to Provide COVID-19 Treatment Options
AbCellera (NASDAQ: ABCL) announced a modified purchase agreement with Eli Lilly to supply 150,000 doses of bebtelovimab to the U.S. government for approximately $275 million. This supply is set to meet current demand through late August 2022, with deliveries starting immediately. An additional option for 350,000 doses is available until September 14, 2022. Bebtelovimab retains neutralization efficacy against prevalent Omicron variants in the U.S. AbCellera's efforts led to the development of significant COVID-19 treatments, including bamlanivimab and bebtelovimab, showcasing its capabilities in pandemic response.
- Modified purchase agreement with Eli Lilly for 150,000 doses of bebtelovimab valued at $275 million.
- Bebtelovimab maintains efficacy against current Omicron variants, ensuring ongoing relevance in the market.
- AbCellera's past achievements in COVID-19 treatment highlight its strong capability in drug development.
- None.
Bebtelovimab continues to maintain neutralization activity against all known variants of interest and concern
Details regarding Lilly's modified purchase agreement to provide the
Bebtelovimab continues to maintain neutralization activity against the most common, and fastest growing, Omicron variants (BA.2.12.1 and BA.4/BA.5) in
About AbCellera’s Response to COVID-19
AbCellera initially mobilized its pandemic response platform against COVID-19 in February of 2020, resulting in the discovery of bamlanivimab, the first monoclonal antibody therapy for COVID-19 to reach human testing and to be authorized for emergency use by the
AbCellera’s second monoclonal antibody for COVID-19, bebtelovimab, was developed to combat emerging variants and. Bebtelovimab maintains binding and neutralizing activity across currently known and reported variants of concern. Bebtelovimab has been studied for the treatment of mild-to-moderate COVID-19 both as a monotherapy and together with other antibodies.
AbCellera’s efforts to respond to the COVID-19 pandemic have identified thousands of unique anti-SARS-CoV-2 human antibodies. These include bamlanivimab, bebtelovimab, and other antibodies that are in various stages of testing by AbCellera and its collaborators.
Bamlanivimab and bebtelovimab were developed from antibodies that were discovered using AbCellera’s pandemic response platform, in partnership with the
AbCellera’s pandemic response capabilities were developed over the past four years as part of the
About
AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce cost, and tackle the toughest problems in drug development. For more information, please visit www.abcellera.com.
AbCellera Forward-looking Statements
This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.
In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the
Source:
View source version on businesswire.com: https://www.businesswire.com/news/home/20220629005715/en/
Media:
Business Development:
Investor Relations:
Source:
FAQ
What is the significance of AbCellera's agreement with Eli Lilly regarding bebtelovimab?
How does bebtelovimab perform against COVID-19 variants?
When will the delivery of bebtelovimab doses begin?
What was AbCellera's response to COVID-19?